InvestorsHub Logo
Followers 0
Posts 94
Boards Moderated 0
Alias Born 08/22/2016

Re: None

Thursday, 11/14/2019 9:09:29 PM

Thursday, November 14, 2019 9:09:29 PM

Post# of 440
During the first year of this limited market release, by March 31, 2019, we sold approximately 300 devices, which were used to perform MCT studies on patents, such that the Company earned combined device sales and technology fee income totally $398,200. Based on our success, in April 2019, we decided to expand sales of the product beyond limited release by doubling the size of our salesforce and our geographic footprint to 11 US states, and the sales pipeline of our product has begun to grow.

In line with its strategy, during the six months ended September 30, 2019, Biotricity almost tripled its fleet of remote patient monitoring devices from the levels of its most recent fiscal year-end, which was March 31, 2019. Biotricity had deployed more than 900 devices as at September 30, 2019. This has resulted in combined device sales and technology fee revenues of $345,906 and $672,906 for the respective three- and six-month periods then ended
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BTCY News